Delcath Systems, Inc. Losses Reach $11.4 Million For The First Half Of 2014

NEW YORK, Aug. 6, 2014 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today reported financial results and operational developments for the fiscal second quarter ended June 30, 2014. Developments for the quarter and recent weeks subsequent to quarter end are as follows:

• Adoption of CHEMOSAT in Europe continued with 50 treatments performed in the first seven months of 2014, as compared to 22 treatments in the same period of 2013
• Since initiation of European commercialization, 123 treatments performed on 83 patients as of July 31, 2014
• Delcath-sponsored Phase 2 study in primary liver cancer (hepatocellular carcinoma or HCC) opened for enrollment at first center in Germany; Johan Wolfgang Goethe University Hospital in Frankfurt
• Two investigator-initiated clinical trials initiated; Leiden University Medical Center, Leiden, Netherlands enrolls and treats first patient in study of CHEMOSAT to treat liver metastasis in colorectal cancer; Johan Wolfgang Goethe University Hospital in Frankfurt trial open for patient enrollment to study use of CHEMOSAT to treat HCC
• Second quarter 2014 quarterly net cash utilization of $4.0 million; Company lowers average cash utilization guidance for the remainder of 2014 to $4 to $5 million a quarter; Cash as of June 30, 2014 was $27.3 million

"We continue to see steady clinical adoption of CHEMOSAT in Europe," commented Jennifer K. Simpson, Interim Co-President & Co-CEO.  "As of July 31st of this year, a total of 50 treatments, of which 22 were retreatments, were performed at leading European cancer centers.  This compares with 22 treatments and six retreatments during the first seven months of 2013.  We believe the growth in performed treatments reflects expanded European clinical experience with CHEMOSAT.  Our company-sponsored clinical program for HCC is also moving forward as the first site in Germany is now active and identifying appropriate patients for enrollment.  In addition to this first site, Johan Wolfgang Goethe University Hospital in Frankfurt, we expect to add additional German sites, as well as sites in the UK and US during the remainder of 2014.  Our goal is to have interim data from the company sponsored Phase 2 studies in the first half of 2015.  We are pleased that two leading centers in Europe have opened their investigator initiated trials and believe that data from these trials will support our European efforts and contribute to our clinical program." 

Financial Results

For the second quarter ended June 30, 2014, total product revenue was $251,000. The company did not record revenue in the year-ago second quarter. Operating expenses decreased by approximately 41% to $6.1 million from $10.3 million for the same period in 2013. The decrease is primarily due to a significant reduction in expenses related to the Company's NDA submission to the FDA, as well as the Company's overall cost management efforts. Operating loss was $5.9 million during the second quarter, as compared with an operating loss of $10.6 million in the same period of the prior year.

For the six months ended June 30, 2014, total product revenue was $561,000, as compared with $81,000 in the year-ago same period.  Operating expenses decreased by approximately 45% to $11.4 million from $20.8 million for the first half of 2013.  The operating loss for the first six months of 2014 was $11.0 million as compared with $20.8 million for the first half of 2013.

Cash and cash equivalents as of June 30, 2014 were $27.3 million. During the quarter, net cash used in operating activities was $4.0 million, a 62% reduction compared to $10.5 million in the comparable period in 2013. The decrease in cash utilization was in part due to a reduction in NDA submission-related costs, and improved organizational and operational efficiencies.

"Our cash utilization, which again was lower than our guidance, demonstrates our continuing efforts to reduce our operational costs and focus on key priorities. Recent expense reduction initiatives include a sublease agreement for 50% of our corporate offices for the remaining lease term of approximately seven years.  As a result of this transaction, we expect to achieve total net savings of $2.6 million over the lease term.  In addition, as a result of our successful efforts, we are revising our forecasted average quarterly cash utilization lower to a range of $4 to $5 million for the remaining quarters of 2014, as compared to our previous average quarterly cash utilization guidance of $5 to $6 million," said Graham G. Miao, Interim Co-President and Co-CEO.

Conference Call and Webcast

The Company will host a conference call today, August 6, 2014 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2014, and provide an update on recent corporate progress. 

The dial-in numbers for the conference call are 877-703-6105 (U.S. participants) and 857-244-7304 (international participants); both numbers require passcode: 33935953. To access the live webcast, go to the Events & Presentations page on the Investor Relations section of the Company's website at http://www.delcath.com/investors/events/.

A taped replay of the call will be available beginning approximately two hours after the call's conclusion and will be available for seven days. Dial-in numbers for the replay are 888-286-8010 and 617-801-6888 for U.S. and International callers, respectively. The replay passcode for both U.S. and International callers is 93152789.  An archived webcast will also be available at http://www.delcath.com/investors/events/.

About Delcath Systems
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device combination product, the Delcath Hepatic Delivery System, is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. Outside of the United States, our proprietary product to deliver and filter melphalan hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for melphalan hydrochloride. The Company obtained authorization to affix a CE Mark for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT Delivery System for Melphalan in Europe. The Delcath Hepatic Delivery System for Melphalan has not been approved for sale in the United States by the U.S. Food and Drug Administration. The Company has initiated plans to investigate Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System for primary liver cancer.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company's ability to achieve the estimated average quarterly cash utilization for 2014, the timing of site activation and subject enrollment in the HCC Phase II global clinical  trial, the time to complete the HCC Phase II global clinical trial program and the results of the same, the timing and results of future clinical trials including without limitation Company sponsored clinical trials or investigator initiated trials, continued clinical adoption, use and resulting, sales, if any, of the CHEMOSAT system in Europe including the UK and Germany, the Company's ability to successfully commercialize the Melphalan HDS/ CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, the Company's ability to satisfy the requirements of the FDA's Complete Response Letter and provide the same in a timely manner, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company's ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company's ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission.

To read full press release, please click here.

Help employers find you! Check out all the jobs and post your resume.